Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis 		0.110 GeneticVariation disease BEFREE In summary, we identified in this study a new variant associated with RA in SUPT20H gene. 30845214 2019
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis 		0.110 SusceptibilityMutation disease CLINVAR
CUI: C2697758
Disease: Interleukin 10 Measurement
Interleukin 10 Measurement 		0.100 GeneticVariation phenotype GWASCAT Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans. 22205395 2012
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.020 AlteredExpression disease BEFREE Therefore, it can be concluded that the reduced expression of C13orf19 in PCa is not involved in the malignant transformation of the cells. 16685401 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.020 AlteredExpression disease BEFREE Quantitative real-time PCR was performed for C13orf19, a gene located on chromosome 13q and previously described to be down-regulated in prostate carcinoma, on different cancer cell lines, on matched prostate tissues from 61 patients with prostate carcinoma and on matched kidney tissues from 23 patients with renal clear cell carcinoma. 15978328 2005
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.010 AlteredExpression disease BEFREE Herein we provide the first report that p38-p38IP is required for the Snail-induced E-cadherin down-regulation and cell invasion in HNSCC. 27531877 2016
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 AlteredExpression phenotype BEFREE Herein we provide the first report that p38-p38IP is required for the Snail-induced E-cadherin down-regulation and cell invasion in HNSCC. 27531877 2016
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.010 AlteredExpression disease BEFREE Therefore, it can be concluded that the reduced expression of C13orf19 in PCa is not involved in the malignant transformation of the cells. 16685401 2006
CUI: C1608408
Disease: Malignant transformation
Malignant transformation 		0.010 AlteredExpression phenotype BEFREE Therefore, it can be concluded that the reduced expression of C13orf19 in PCa is not involved in the malignant transformation of the cells. 16685401 2006
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.010 AlteredExpression group BEFREE Quantification of C13orf19/P38IP mRNA expression by quantitative real-time PCR in patients with urological malignancies. 15978328 2005
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.010 AlteredExpression disease BEFREE Quantitative real-time PCR was performed for C13orf19, a gene located on chromosome 13q and previously described to be down-regulated in prostate carcinoma, on different cancer cell lines, on matched prostate tissues from 61 patients with prostate carcinoma and on matched kidney tissues from 23 patients with renal clear cell carcinoma. 15978328 2005
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney 		0.010 AlteredExpression disease BEFREE In contrast, C13orf19 mRNA alterations in expression seemed to be random events in kidney cancers. 15978328 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.010 Biomarker group BEFREE Previously, we identified human papillomavirus type 16 (HPV-16) E5 as a tumor rejection antigen that can induce cytotoxic T lymphocytes (CTLs) to protect against tumor growth (D. W. Liu et al., J. Virol.74:9083-9089, 2000). 14722288 2004
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.010 AlteredExpression disease BEFREE Several of the most highly expressed genes identified by sequencing, such as a novel putative disulfide isomerase (MGC3178), tumor rejection antigen TRA1, heat shock 70-kDa protein 5, and annexin A2, were also differentially expressed between myeloma and B lymphoma cell lines using this myeloma-enriched microarray. 12200383 2002
CUI: C0004565
Disease: Melanoma, B16
Melanoma, B16 		0.010 Biomarker disease BEFREE The transgene, murine tyrosinase-related protein 2 (mTRP-2), encodes a clinically relevant melanoma-associated antigen (MAA), which has been found to be a tumor rejection antigen for B16 melanoma. 11779404 2001
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.010 AlteredExpression group LHGDN Identification of a novel gene on chromosome 13 between BRCA-2 and RB-1. 11340631 2001
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.010 Biomarker disease BEFREE A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. 10987294 2000
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 AlteredExpression disease BEFREE Expression of the SART-1 tumor rejection antigen in breast cancer. 9935232 1999
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 AlteredExpression disease BEFREE Expression of the SART-1 tumor rejection antigen in breast cancer. 9935232 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease BEFREE The possibility of tumor rejection antigen, encoded by the MAGE-1 gene, being a target for immunotherapy in hepatocellular carcinoma (HCC) patients and the cloning of the full-length cDNA of this gene for subsequent studies were explored with the aim of discovering new immunotherapeutic strategies for HCC. 10592101 1999